Mitoxantrone 2HCl
Mitoxantrone 2HCl structure
|
Common Name | Mitoxantrone 2HCl | ||
|---|---|---|---|---|
| CAS Number | 70476-82-3 | Molecular Weight | 517.403 | |
| Density | N/A | Boiling Point | 805.7ºC at 760 mmHg | |
| Molecular Formula | C22H30Cl2N4O6 | Melting Point | 203-205ºC | |
| MSDS | Chinese USA | Flash Point | 441.1ºC | |
| Symbol |
GHS08 |
Signal Word | Danger | |
|
Molecular mechanism of T-cell protein tyrosine phosphatase (TCPTP) activation by mitoxantrone.
Biochim. Biophys. Acta 1834(10) , 1988-97, (2013) T-cell protein tyrosine phosphatase (TCPTP) is a ubiquitously expressed non-receptor protein tyrosine phosphatase. It is involved in the negative regulation of many cellular signaling pathways. Thus, activation of TCPTP could have important therapeutic applic... |
|
|
Phase II trial assessing granulocyte-macrophage-colony stimulating factor, ketoconazole plus mitoxantrone in metastatic castration-resistant prostate cancer progressing after docetaxel treatments.
Cancer Invest. 31(3) , 177-82, (2013) This study evaluated objective response and safety for the combination of granulocyte macrophage-colony stimulating factor (GM-CSF), ketoconazole, and mitoxantrone in castration-resistant prostate cancer (CRPC) patients who previously failed docetaxel-based c... |
|
|
Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma.
Br. J. Haematol. 166(4) , 625-8, (2014)
|
|
|
Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma.
Pediatr. Blood Cancer 61(5) , 810-4, (2014) Daunorubicin, a component of the four-drug induction chemotherapy regimen for de novo pediatric high-risk acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LLy), was unavailable in 2011 due to a national drug shortage. During this time, our insti... |
|
|
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.
J. Natl. Cancer Inst. 105(22) , 1729-37, (2013) Several prognostic models for overall survival (OS) have been developed and validated in men with metastatic castration-resistant prostate cancer (mCRPC) who receive first-line chemotherapy. We sought to develop and validate a prognostic model to predict OS i... |
|
|
Cladribine in the treatment of acute myeloid leukemia.
Leuk. Res. 38(4) , 425-7, (2014)
|
|
|
Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure
Leuk. Res. 38(4) , 443-6, (2014) For patients with acute myeloid leukemia from antecedent myelodysplastic syndrome particularly after azanucleoside treatment failure, outcome is poor. Here, we conducted a case-control study in these patients to compare the efficacy of CLAG-M induction (28 pa... |
|
|
Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia.
Leuk. Res. 38(12) , 1441-5, (2014) The survival of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) is poor. We performed a retrospective analysis of 40 patients treated with five days of mitoxantrone 8mg/m(2)/day, etoposide 100mg/m(2)/day, and cytarabine 1000mg/m(2)/day... |
|
|
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
Cancer 121(2) , 234-42, (2015) CPX-351 is a liposome-encapsulated fixed-molar-ratio formulation of cytarabine and daunorubicin that exploits molar ratio-dependent drug-drug synergy to enhance antileukemic efficacy.This phase II study randomized 125 patients 2:1 to CPX-351 or investigators'... |
|
|
Clinical efficacy of mitoxantrone and Ara-C with or without etoposide salvage chemotherapy in adult patients with relapsed or refractory acute lymphoblastic leukemia: retrospective multicenter study of the Korean Adult ALL Working Party.
Acta Haematol. 133(1) , 91-7, (2015) Mitoxantrone is a conventional agent for relapsed or refractory acute lymphoblastic leukemia (ALL). However, an effective combination with other drugs and a feasible dosage has not been identified. A retrospective study of 46 patients with relapsed or refract... |